Comparing antimalarial drugs and their effects over the Plasmodium lifecycle

February 21, 2012

In this week's PLoS Medicine, Michael Delves of Imperial College London, UK and colleagues compare the activity of 50 current and experimental antimalarials against liver, sexual blood, and mosquito stages of selected human and nonhuman parasite species, including Plasmodium falciparum, Plasmodium berghei, and Plasmodium yoelii.

These results provide a valuable guide to help researchers decide which drugs and compounds show most promise as potential future for blocking the transmission of malaria.

The authors say: "This information might guide decisions regarding which molecules could be optimally combined to provide the next generation of drugs that will succeed to artemisinin combination therapies (ACTs) and support the eradication of malaria. This comprehensive approach to drug discovery has potential utility for targeting other pathogens with complex life cycles."

More information: Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, et al. (2012) The Activities of Current Antimalarial Drugs on the Life Cycle Stages of Plasmodium Life Cycle: A Comparative Study with Human and Rodent Parasites. PLoS Med 9(2): e1001169. doi:10.1371/journal.pmed.1001169

Related Stories

Recommended for you

Gut environment could reduce severity of malaria

February 8, 2016

Microorganisms in the gut could play a role in reducing the severity of malaria, according to a new study co-authored by researchers at the University of Tennessee, Knoxville, and the University of Louisville.

Easier diagnosis for fungal infection of the lungs

January 18, 2016

A new clinical imaging method developed in collaboration with a University of Exeter academic may enable doctors to tackle one of the main killers of patients with weakened immune systems sooner and more effectively.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.